HeartCare Medical-B (06609.HK) Surges Over 13% on Strong Full-Year Profit Turnaround; Plans to File for STAR Market IPO

According to the Zhisheng Finance APP, HeartCare-B (06609) surged over 13% again, with cumulative gains exceeding 40% post-results. As of press time, it rose 8.24%, trading at HK$59.1, with a turnover of HK$13.4367 million.

On the news front, HeartCare recently released its annual performance report, showing that the company achieved a total revenue of 408 million yuan for the full year, representing a year-on-year increase of 46.9%. Meanwhile, the company's gross profit margin remained stable at over 70%, with a net profit reaching 83.34 million yuan, marking a significant turnaround from losses to profits compared to the previous year. This indicates that the company’s strategic layout in the neurointervention field has entered a harvest period. Notably, the company plans to submit an application for listing on China's STAR Market by 2026.

The company's management proposed multiple development goals at the earnings meeting: maintaining annual revenue growth of no less than 35% over the next three years, and striving to achieve the top market share among China-produced neurointerventional brands by 2028; regarding overseas revenue, it is expected to contribute more than 10%, with a scale exceeding 100 million RMB, by 2028; on the profit side, the aim is to achieve a net profit margin of approximately 20%, with a gross margin expected to stabilize in the range of 68%-70%, ensuring stable profitability through meticulous cost management and economies of scale.